 |

WHO ARE BIOCURE'S INVESTORS?
WHERE DOES BIOCURE STAND TODAY?
WHO ARE BIOCURE'S MANAGEMENT?
WHO ARE BIOCURE'S SCIENTIFIC ADVISORY BOARD?
WHO IS ON BIOCURE'S BOARD OF DIRECTORS?
Who
are BioCure's Investors?
Our
first round of investment, completed in September 1999, was made
by the original supporters of the seed project within CIBA Vision:
| ::: |
CIBA
Vision, Switzerland and USA
 |
| ::: |
Novartis
Venture Fund, Switzerland
 |
| ::: |
CRCERT/CSIRO,
Australia
 |
| ::: |
Institute
for Eye Research, Australia
 |
We completed a second round of investment in August 2006 with the
support of the original investors. A leading spine and orthopedic
company made a new investment in BioCure Inc.
Where
does BioCure stand today?
BioCure
continues to reinvest its financial returns from its license to
and its manufacturing collaboration with Biocompatibles UK Ltd.
By restricting its focus to R&D and manufacturing, BioCure has
been able to continue to partner with leading commercial and research
partners in the therapeutic areas of spine and orthopedic and woundcare.
These programs target short and medium-term regulatory approvals.
We are seeking to expand collaborations in these sectors.
Additionally, we have recently formed a Swiss subsidiary company,
BioCure (Schweiz) GmBH, which is focused on the development of our
intellectual capital in the exciting area of nanotechnology. We
are actively seeking new collaborations and, potentially, new investors
as we develop a detailed product pipeline.
Who
are BioCure's management?
We
have an experienced management team supported by highly trained
and innovative researchers in the areas of polymer science, cell
biology, engineering, manufacturing and quality control.
Dr.
Adrian Hunter is the CEO, President and co-Founder of BioCure.
He has more than 32 years experience in the healthcare field, mostly
in senior management positions. His experience spans operations,
finance, marketing and R&D. He proposed and negotiated the spin-off
of BioCure from Novartis.
On
leaving University in 1969, he joined Scientific Control Systems,
Ltd. as a consultant. In 1973 he joined CIBA-Geigy (UK), Ltd. -
now part of the Novartis
Group - as Head of Mathematics, Statistics, and Computing. He then
held several positions within the Pharmaceutical Division - P.A.
to the Managing Director in the UK, Product Manager and Financial
Analyst in Switzerland, returning to the UK as Director (VP) of
Business Development and member of the Pharmaceutical Management
Committee. In the latter position he set up CIBA Consumer Pharmaceuticals
in the UK.
In
1985, he joined Titmus Eurocon (a member of the CIBA Vision Group)
in Germany, responsible for CIBA
Vision's world-wide (ex. USA) marketing and sales. He joined
the world-wide Management Committee of CIBA Vision as Director (VP)
of Finance in 1987 and later served as the Head of European Operations.
In 1991, he became Group Vice President with world-wide responsibilities
for R&D and marketing, based initially in Switzerland, and from
1993, in Atlanta.
During
his time with CIBA Vision, he was responsible for successfully negotiating
several acquisitions and other important contracts. He was heavily
involved in the development and implementation of CIBA Vision's
long-term strategy. He has a specific interest in breakthrough projects
and process innovation and the organization and management of multi-disciplined
teams. He managed two major breakthrough projects at CIBA Vision.
This led to the introduction of the world's first true extended
wear soft contact lens, Night & Day, and to the Dailies disposable
contact lens - CIBA Vision's most successful product to date - based
on a novel, low cost, contact lens manufacturing process.
Dr.
Hunter is a graduate of London University in Mathematics and Physics
(1st class honors), with a Ph.D. in Theoretical Physics. He also
has a Certified Diploma in Accounting and Finance.
Mr.
Andrew Maslaveckas is Co-Founder and Chief Operating Officer
of BioCure responsible for all of BioCure’s research and commercial
operations. Mr. Maslaveckas has over 28 years of experience in managing
and building both consumer and professional health care companies.
Prior to the establishment of BioCure, Mr. Maslaveckas, as Head
of New Growth Businesses at CIBA
Vision, was primarily responsible for identifying the commercial
and market rationale for BioCure's spin-off from Novartis.
Joining Ciba Vision in 1993, Mr. Maslaveckas, as Global Head of
Contact Lenses, was charged with developing and implementing an
aggressive strategy to build a significant presence in the disposable
contact lens segment and to grow CIBA Vision's contact lens profitability
and market share in the contact lens business in the face of strong
competition from Johnson & Johnson and Bausch & Lomb. During
his tenure, CIBA Vision's sales revenues increased over 30% per
annum and approached $500 million with excellent returns on sales
and capital.
Prior to 1993, Mr. Maslaveckas worked for 14 years with Johnson
& Johnson in a number of executive positions in the consumer
and professional businesses.
In 1989, he joined Vistakon UK in its first year as Managing Director
responsible for relaunching its ACUVUE* disposable contact lens
franchise following initial revenue and financial disappointments.
Mr. Maslaveckas initiated a highly successful campaign which culminated
in Vistakon achieving the #1 position in the market in his second
year and building the business to J&J's largest revenue brand
in the UK through aggressive consumer and professional initiatives.
In 1991, Mr. Maslaveckas added responsibilities for Vistakon Germany
and later joined both the J&J UK Board and was Vistakon's representative
on the European Management Committee of J&J's Professional segment.
In 1985, Mr. Maslaveckas, following a regional assignment in Morocco,
was named as the first Managing Director of the company and charged
with the establishment of a sales, marketing and manufacturing presence
and infrastructure. During his six years in Morocco, the company
became the #1 market leader in the baby toiletries, sanitary protection
and shampoo markets through aggressive and innovative commercial
programs. Latterly, the company assumed responsibilities for J&J's
professional and pharmaceutical franchises.
Mr. Maslaveckas joined J&J in the UK as an Area Manager and
subsequently a Regional Manager in its sales and marketing department
charged with P&L responsibility for distributor territories
in Southern Europe, Africa and the Middle East.
Mr. Maslaveckas graduated M.A. (Hons) in French and Russian from
the University of Glasgow in 1977.
Dr.
Dennis Goupil is the Chief Technical Officer and Vice President
of Research and Development. He brings over 25 years experience
in medical research and product development, including 15 years
at the Director / Vice President level. In total, Dr. Goupil has
directed the product development of over 20 commercial products.
Throughout his career, Dr. Goupil has also had responsibilities
for managing intellectual property, conducting clinical trials,
technical assessments for mergers and acquisitions, and leading
the technical team in transferring new businesses obtained through
acquisition.
Dr. Goupil started his research career in medical devices as part
of the team that developed the total artificial heart in the 1970s.
His responsibilities included conducting interfacial studies at
the polymer-blood interface that led to the choice of materials
for the artificial heart. Following this research, Dr. Goupil was
responsible for the development of a surface chemistry laboratory
in central R&D for American Cyanamid where his team conducted
research on medical devices and pharmaceutical products. He then
joined American Cyanamid's Davis & Geck division with responsibilities
for developing new product opportunities for degradable polymers.
This research was conducted during the pioneering days of degradable
polymers and led Dr. Goupil into tissue engineering and degradable
devices in orthopaedics (pins, screws, plates), plastic surgery
(nerve regeneration tubes), vascular surgery (small diameter grafts,
vessel clamp), and general surgery (bowel anastomosis rings, staples).
In this role, Dr. Goupil was also responsible for managing the intellectual
property for Davis & Geck.
Following Davis & Geck, Dr. Goupil joined Cytotherapeutics where
he led the product development and scale-up of a novel cellular-based
implant that was focused on treating neurological diseases such
as Parkinson's disease. He later joined Pharmacia Ophthalmics as
Vice-President of R&D for intraocular lens and medical device
product development. Following relocation back to the northeast
for personal reasons, Dr. Goupil was Vice-President of R&D for
Datascope's Cardiac Assist Division where he directed the development
of new intra-aortic balloons and in the establishment of a clinical
trial to evaluate the use of immediate IAB therapy for heart attack
patients. Lastly, just prior to joining BioCure, Dr. Goupil was
responsible for biomaterials and surgical product development for
the Meditech division of Boston Scientific. In this role, he developed
and commercialized vascular grafts and fabrics used by the vascular
surgeon. He also led the technical evaluation of several potential
acquisitions and license agreements, including the management of
the transfer of technology and staff associated with acquired companies.
Dr. Goupil holds a Ph.D. in Physical Chemistry from Clarkson College
of Technology, a M.S. in engineering from the University of Cincinnati,
a B.S. in chemistry from Niagara University.
Dr.
Thomas Hirt is Vice President of Research and Development
and General Manager of BioCure (Schweiz) GmBH.
Dr. Hirt joined Ciba Geigy AG in 1995 working at its Central Research
Unit in Basel, Switzerland. After one year, he transferred to Ciba
Vision in Atlanta, USA as a Senior Scientist working primarily on
developing new polymeric materials for extended wear contact lenses.
In this context, he also synthesized amphiphilic triblock copolymers,
that were used to make the first hollow, polymeric nanovesicles
in water.
After 3 years at Ciba
Vision, he moved back to Switzerland to head up the Research
and Development and New Business Development efforts at SEFAR, Printing
Division. During the 8 years at SEFAR AG, as a member of the Divisional
Management, he implemented state of the art R&D procedures,
increased sales of new products from annual growth in the low single
digits to high double digits percentages. At SEFAR, he gained experience
in contract negotiations, business processes, product development
and project and technology management.
Dr. Hirt joined BioCure in January 2007 to lead the start-up of
BioCure Switzerland whose primary focus is on nanotechnology. As
an original inventor, he is responsible for the business and product
development of the hollow, polymeric nanovesicles. He is also responsible
for the corporate materials development group.
Dr. Hirt is a graduate from ETH in Zurich in Technical Chemistry,
conducted his PhD in polymer science and holds a Diploma in Marketing.
The subject of his PhD is the synthesis and characterization of
new degradable polymers for medical applications.
Who are BioCure's Scientific Advisory Board?
| ::: |
Professor
Jennifer West, Ph.D., Rice University
 |
| ::: |
Michael
K. Schaufele, The Emory Clinic
 |
Who
is on BioCure's Board of Directors?
| ::: |
Tariq
Aziz , CIBA
Vision
 |
| ::: |
Ruedi
Gygax, Novartis
Venture Fund
 |
| ::: |
Brien
Holden, CRCERT
 |
| ::: |
Adrian
Hunter, BioCure
 |
Please
contact us if you have any questions.
We'd be happy to provide you with more information.
|
  |
|